For over 50 years, Guthrie has been conducting oncology clinical trials and we are proud to have been affiliated with multiple institutions, including University of Rochester, Cornell University and Vanderbilt. Our current collaborator for National Cancer Institute (NCI) trials is the Mayo Clinic in Rochester, Minnesota. This collaboration allows access to trials through the NCI’s National Clinical Trials Network (NCTN), a research network that provides treatment, screening, and diagnostic trials to over 3,000 clinical sites across the nation. Through this partnership, we’re able to begin clinical trials quickly, reach conclusions faster and offer studies that incorporate precision medicine and novel therapies that otherwise may not be available.  

Leading-edge research delivered locally - As a Guthrie patient you may have the unique opportunity to take part in one or more of nearly 100 clinical research trials that involve new investigational treatments for many cancer types, and the potential to participate in select trials of novel cancer drugs. If you’re at risk for certain types of cancer, screening and prevention trials are also available. Guthrie research scientists are investigating several projects designed to explore cancer trends in our region and how they may affect the next generation of residents.

Clinical Trials

Clinical trials study new ways to prevent, detect and treat cancer. The NCI approves, oversees and provides funding for a large percentage of oncology clinical trials conducted each year in the United States. Guthrie’s participation in this network provides you access to valuable clinical trials without the burden and expense of traveling to a major metropolitan area.

As a result, you receive excellent care locally from the Guthrie Cancer Center team, while still being able to access cutting edge investigational therapies that are offered in large university settings and metropolitan areas. Clinical cancer trials might involve preventive measures and/or treatments, including chemotherapy, biotherapy, supportive care medications, radiation, experimental surgical techniques or devices, lab draws and/or alternative medicines. 

Your physician can present you with options and help you determine whether a clinical trial is right for you. Most clinical trials offered at Guthrie are phase 2 or phase 3 studies which measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, biotech companies, and the NCTN to offer you the chance to get innovative treatments, novel therapies and to assist with the future of cancer care. 

Title: S1802, Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer).
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Details (Identifier #): 03678025
Title: S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator:

Gergel MD, Thomas

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT04155034
Title: S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator:

Bertsch MD, David

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT03860883
Title: S2302, PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: Cancer Trials Support Unit-
Details (Identifier #): NCT05633602
Title: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III
Study
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT05929768
Title: Tethered Enzyme Technology (TET) Assay for
Detection of COVID-19
Department: Internal Studies
Diagnosis: Infectious Disease
Principal Investigator:

Prabhu MD, Sheela

Sponsors: Internal Foundation
Details (Identifier #): None
Title: Tethered Enzyme Technology (TET) Assay for Quantitative Diagnosis of Blunt Head Trauma (BHT) and Stroke through Detection of Blood and Saliva Biomarkers
Department: Trauma
Diagnosis: Neurology
Principal Investigator:

Behm MD, Robert

Sponsors: Internal
Details (Identifier #): None
Title: The Efficacy of Steroid-Sparing Anti-Emetic Therapy in Patients Treated with High Emetogenic Chemotherapy; Single Center Non-Inferiority Open Label Randomized Controlled Trial
Department: Oncology
Diagnosis: Miscellaneous
Principal Investigator:

Ink PharmD, Nicole

Sponsors: Internal Foundation
Details (Identifier #): NCT05590923
Title: The PROACT LUNG Study: A Prospective Observational Clinical Validation Study of the Freenome Multiomics Blood Test for Lung Cancer Screening
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator:

McGinley DO, Kathleen

Sponsors: Freenome, Inc
Details (Identifier #): NCT06122077
Title: The PROACT LUNG Study: A Prospective Observational Clinical Validation Study of the Freenome Multiomics Blood Test for Lung Cancer Screening
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator:

Bertsch MD, David

Sponsors: Freenome, Inc
Details (Identifier #): NCT06122077